Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
R&D
Biotech
Gilead culls last MASH program, 2 cancer assets
The dropped oncology assets are a DGKα inhibitor and an MCL1 inhibitor, which join a Novo-partnered MASH program in the scrap heap.
Darren Incorvaia
Aug 8, 2025 11:50am
BioNTech cuts 90 more US jobs as part of pipeline realignment
Aug 5, 2025 1:24pm
AbbVie ends development of IL-1 asset in ulcerative colitis
Jul 31, 2025 12:32pm
Lilly links up with Gate in $856M biobucks deal
Jul 24, 2025 2:32pm
TCG Labs Soleil raises $400M for single-asset biotechs
Jul 24, 2025 7:00am
GSK plans 'very limited' job cuts for global R&D team
Jul 15, 2025 4:15pm
